科伦药业：科伦博泰生物创新研发管线共布局30余项

Core Viewpoint - Kelun Pharmaceutical has significant ownership in Kelun Biotech and is actively developing a diverse pipeline of innovative drugs targeting various diseases [2] Company Summary - As of June 30, 2025, Kelun Pharmaceutical directly holds 51.45% of Kelun Biotech and indirectly holds 4.97% [2] - Kelun Biotech has over 30 innovative drug candidates in its research pipeline, focusing on oncology and non-oncology diseases such as autoimmune and metabolic disorders [2]